Moderna signs mRNA access deals with Korean universities

The United States biotech and pharmaceutical company Moderna on 15 September announced signings of contracts with the academic-industry cooperation foundations of Korea University Medical Center in Seoul and Chosun University in Gwangju on the research and development of medicines using the messenger ribonucleic acid, or mRNA, platform, writes Ji-Hyun Lee for the The Korea Economic Daily.

Moderna said it will launch its global public health programme mRNA Access starting with South Korea. The programme’s goal is to accelerate new vaccine development through collaboration with global partners using Moderna’s mRNA technology.

“KUMC [Korea University Medical Center] considers it highly significant to have the opportunity to research and develop the infinite potential of mRNA through this mRNA Access programme concluded with Moderna,” said Kim Hak-jun, president of KUMC’s Medical Research and Business Foundation.
Full report on The Korea Economic Daily site